Cover Image
市場調查報告書

全球治療HIV/AIDS用抗逆轉錄病毒藥的開發產品·開發平台分析

A Global Product and Pipeline Analysis of Antiretroviral Drug Development for the Treatment of HIV/AIDS

出版商 Frost & Sullivan 商品編碼 307680
出版日期 內容資訊 英文 66 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球治療HIV/AIDS用抗逆轉錄病毒藥的開發產品·開發平台分析 A Global Product and Pipeline Analysis of Antiretroviral Drug Development for the Treatment of HIV/AIDS
出版日期: 2014年07月03日 內容資訊: 英文 66 Pages
簡介

本報告以治療HIV/AIDS用的抗病毒藥/抗逆轉錄病毒藥為焦點,彙整上市藥·開發中的產品·開發平台評估,治療HIV感染的組合方案,各類藥物的區分,臨床實驗計劃·結果,銷售計劃的實際成果與預測,全球各地各國的得病率等。

第1章 摘要整理

第2章 調查手法·範圍

第3章 簡介

  • HIV概要
  • HIV/AIDS的得病率:全球·各地區
  • 市場區隔

第4章 HIV/AIDS抗逆轉錄病毒藥市場

  • HIV/AIDS抗逆轉錄病毒藥市場:上市藥的競爭情形
  • HIV/AIDS抗逆轉錄病毒藥市場:開發中產品的競爭情形
  • HIV/AIDS抗逆轉錄病毒藥市場:產品銷售·專利到期的計劃
  • HIV/AIDS抗逆轉錄病毒藥市場:主要的第三期臨床試驗
  • HIV/AIDS抗逆轉錄病毒藥市場:最新的主實驗結果
  • 上市藥概要:多級FDC產品
  • 上市藥概要:單一級的FDC產品
  • 上市藥概要:Single-entity Products
  • 開發平台藥物概要:後期階段的開發產品
  • 開發平台藥物概要:初期臨床開發產品
  • 開發平台藥物概要:初期開發產品

第5章 結論·建議

  • 結論·建議
  • 免責聲明

第6章 附錄

第7章 FROST & SULLIVAN

目錄
Product Code: NE48-01-00-00-00

Antiretroviral Combinations Continue to Transform the Treatment Landscape

This research service focuses on antiviral/antiretroviral therapeutics for the treatment of HIV/AIDS. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HIV infection. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and global prevalence by region and country. Key market developments since Q1 2013 and key companies to watch are also included. This research service is an update of the 2013 research service titled Strategic Analysis of Antiviral Drug Development for Viral Hepatitis and HIV/AIDS.

Table of Contents

1. EXECUTIVE SUMMARY

  • 1. Key Market Developments since Q1 2013
  • 2. Key Findings
  • 3. Evolution of Standard of Care for HIV
  • 4. Key Companies to Watch

2. METHODOLOGY AND SCOPE

  • 1. Methodology and Scope

3. INTRODUCTION

  • 1. HIV Overview
  • 2. HIV Overview (continued)
  • 3. Prevalence of HIV/AIDS Globally and by Region
  • 4. Market Segmentation
  • 5. Market Segmentation (continued)

4. HIV/AIDS ANTIRETROVIRAL MARKET

  • 1. HIV/AIDS Antiretroviral Market-Competitive Landscape ofMarketed Products
  • 2. HIV/AIDS Antiretroviral Market-Competitive Landscape ofProducts in Development
  • 3. HIV/AIDS Antiretroviral Market-Product Launch and Patent Expiration Timeline
  • 4. HIV/AIDS Antiretroviral Market-Major Phase 3 Ongoing Trials
  • 5. HIV/AIDS Antiretroviral Market-Major Phase 3 Ongoing Trials (continued)
  • 6. HIV/AIDS Antiretroviral Market-Recent Pivotal Trial Results
  • 7. HIV/AIDS Antiretroviral Market-Recent Pivotal Trial Results (continued)
  • 8. Marketed Product Synopsis-Multi-class FDC Products
  • 9. Marketed Product Synopsis-Single-class FDC Products
  • 10. Marketed Product Synopsis-Single-entity Products
  • 11. Marketed Product Synopsis-Single-entity Products (continued)
  • 12. Marketed Product Synopsis-Single-entity Products (continued)
  • 13. Marketed Product Synopsis-Single-entity Products (continued)
  • 14. Marketed Product Synopsis-Single-entity Products (continued)
  • 15. Marketed Product Synopsis-Single-entity Products (continued)
  • 16. Marketed Product Synopsis-Single-entity Products (continued)
  • 17. Pipeline Synopsis-Late-stage Development Products
  • 18. Pipeline Synopsis-Late-stage Development Products (continued)
  • 19. Pipeline Synopsis-Late-stage Development Products (continued)
  • 20. Pipeline Synopsis-Late-stage Development Products (continued)
  • 21. Pipeline Synopsis-Late-stage Development Products (continued)
  • 22. Pipeline Synopsis-Late-stage Development Products (continued)
  • 23. Pipeline Synopsis-Early Clinical Development Products
  • 24. Pipeline Synopsis-Early Development Products
  • 25. Pipeline Synopsis-Early Development Products (continued)
  • 26. Pipeline Synopsis-Early Development Products (continued)

5. CONCLUSIONS AND RECOMMENDATIONS

  • 1. Conclusions and Recommendations
  • 2. Legal Disclaimer

6. APPENDIX

  • 1. Decision Support Database-Prevalence of HIV Infection
  • 2. Decision Support Database-Prevalence of HIV Infection (continued)
  • 3. Decision Support Database-Prevalence of HIV Infection (continued)
  • 4. Decision Support Database-Prevalence of HIV Infection (continued)
  • 5. Decision Support Database-Prevalence of HIV Infection (continued)
  • 6. Decision Support Database-Prevalence of HIV Infection (continued)
  • 7. Decision Support Database-Prevalence of HIV Infection (continued)
  • 8. Decision Support Database-Prevalence of HIV Infection (continued)
  • 9. Decision Support Database-Prevalence of HIV Infection (continued)
  • 10. Decision Support Database-Prevalence of HIV Infection (continued)

7. THE FROST & SULLIVAN STORY

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition: Future of Your Company & Career
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top